Idea principal
Across 117 studies with 3,202,496 participants, the highest versus lowest Mediterranean diet adherence was linked to lower cancer mortality (RR 0.87, 95% CI 0.82-0.92) and lower risk of several site-specific cancers. Most comparisons were rated low or very low certainty, and observational studies cannot show that the diet itself caused the difference.
Study design
Revisión de evidencia
Reading basis
Published abstract
Reading focus
Design & applicability
Esta explicación editorial está disponible en inglés, chino simplificado y chino tradicional. Esta interfaz muestra la lectura en inglés.
Pregunta de investigación
Whether eating a Mediterranean-style diet lowers cancer risk has been studied many times with mixed strength of evidence. The authors updated an earlier review to ask how adherence relates to cancer mortality, specific cancers, and deaths and recurrence among cancer survivors.
Población y método
Systematic review and random-effects meta-analysis of randomized controlled trials, case-control studies and cohort studies published up to April 2020 (PubMed and Scopus). Risk estimates were pooled for the highest versus lowest category of Mediterranean diet (MedDiet) adherence. Certainty of evidence for cohort studies and trials was graded with the NutriGrade scoring system. The updated search found 44 new studies; 117 studies were meta-analysed.
Resultados
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1Highest adherence was inversely associated with cancer mortality (RR 0.87, 95% CI 0.82-0.92; 18 cohort studies) and with all-cause mortality among cancer survivors (RR 0.75, 95% CI 0.66-0.86; 8 studies).
- 2For cancer types, higher adherence was linked to lower risk of breast (RR 0.94, 95% CI 0.90-0.97; 23 studies), colorectal (0.83, 0.76-0.90; 17), head and neck (0.56, 0.44-0.72; 9), respiratory (0.84, 0.76-0.94; 5 cohort studies), gastric (0.70, 0.61-0.80; 7), bladder (0.87, 0.76-0.98; 4) and liver cancer (0.64, 0.54-0.75; 4).
- 3No change in risk was seen for blood, esophageal, pancreatic and prostate cancer.
- 4Moderate certainty of evidence came from cohort studies for cancer mortality and colorectal cancer; most other comparisons were rated low or very low certainty.
Límites e incertidumbre
- 1Most comparisons were graded low or very low certainty, so many of the site-specific results could change with better studies.
- 2Most estimates pool observational studies, where people who follow a Mediterranean diet may also differ in smoking, activity and income, so the diet may not be the cause.
- 3The highest-versus-lowest comparison depends on how each study scored adherence, which the abstract does not describe.
- 4This reading is based on the abstract only.
Relevancia práctica
The findings fit a pattern in which people who eat more vegetables, fruit, whole grains, legumes, fish and olive oil tend to have fewer cancer deaths, but they do not prove the diet prevents any particular cancer. It is a reasonable pattern of eating on other grounds. People with cancer or at high risk should discuss diet with their care team.
Tus datos
If you keep a food log, you can see how often you eat the foods that make up a Mediterranean pattern and watch the weekly trend. There is no standard score to compare with your device data, so use the log to track your own consistency rather than to estimate cancer risk.
Cómo interpretar la evidencia
Check which designs were included, how searches and bias assessment were conducted, and the last search date. Publication date alone does not make the underlying evidence current.
Resumen estructurado de los autores English
El resumen original en inglés se reproduce con atribución bajo la licencia indicada. Es una fuente, no una interpretación de MoveVitals. El análisis preparado figura arriba; verifica los resultados importantes en la fuente.
Purpose
The aim of current systematic review was to update the body of evidence on associations between adherence to the Mediterranean diet (MedDiet) and risk of cancer mortality, site-specific cancer in the general population; all-cause, and cancer mortality as well as cancer reoccurrence among cancer survivors.
Methods
A literature search for randomized controlled trials (RCTs), case-control and cohort studies published up to April 2020 was performed using PubMed and Scopus. Study-specific risk estimates for the highest versus lowest adherence to the MedDiet category were pooled using random-effects meta-analyses. Certainty of evidence from cohort studies and RCTs was evaluated using the NutriGrade scoring system.
Results
The updated search revealed 44 studies not identified in the previous review. Altogether, 117 studies including 3,202,496 participants were enclosed for meta-analysis. The highest adherence to MedDiet was inversely associated with cancer mortality (RR_(cohort): 0.87, 95% CI 0.82, 0.92; N = 18 studies), all-cause mortality among cancer survivors (RR_(cohort): 0.75, 95% CI 0.66, 0.86; N = 8), breast (RR_(observational): 0.94, 95% CI 0.90, 0.97; N = 23), colorectal (RR_(observational): 0.83, 95% CI 0.76, 0.90; N = 17), head and neck (RR_(observational): 0.56, 95% CI 0.44, 0.72; N = 9), respiratory (RR_(cohort): 0.84, 95% CI 0.76, 0.94; N = 5), gastric (RR_(observational): 0.70, 95% CI 0.61, 0.80; N = 7), bladder (RR_(observational): 0.87, 95% CI 0.76, 0.98; N = 4), and liver cancer (RR_(observational): 0.64, 95% CI 0.54, 0.75; N = 4). Adhering to MedDiet did not modify risk of blood, esophageal, pancreatic and prostate cancer risk.
Conclusion
In conclusion, our results suggest that highest adherence to the MedDiet was related to lower risk of cancer mortality in the general population, and all-cause mortality among cancer survivors as well as colorectal, head and neck, respiratory, gastric, liver and bladder cancer risks. Moderate certainty of evidence from cohort studies suggest an inverse association for cancer mortality and colorectal cancer, but most of the comparisons were rated as low or very low certainty of evidence.
Fuentes y atribución
An updated systematic review and meta-analysis on adherence to mediterranean diet and risk of cancer.
Morze J, Danielewicz A, Przybyłowicz K, Zeng H, Hoffmann G, Schwingshackl L.
European journal of nutrition · 2020-08-08
DOI: 10.1007/s00394-020-02346-6 ↗PubMed · 32770356 ↗Europe PMC · Licencia registrada: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
Interpretación editorial de MoveVitals · contenido educativo · sin revisión clínica individual registrada
Fuentes verificadas 2026-11-01
Guías prácticas
Leer en contexto
Early time-restricted eating linked to more weight loss and lower insulin than late eating
Pooling 41 randomised trials (2287 participants, median intervention 8 weeks), time-restricted eating was associated with 2.15 kg lower body weight than usual diets (95% CI -2.56 to -1.74), and eating early beat eating late by 1.15 kg (95% CI -1.86 to -0.45). Most trials were short, only 6 study arms tested early eating, and the outcomes were body and blood measures, not heart attacks or deaths.
BMJ Medicine
An 8 a.m. to 4 p.m. eating window added to calorie cutting gave no clear extra weight loss
Among 139 patients with obesity on a calorie-restricted diet, adding an eating window of 8:00 a.m. to 4:00 p.m. led to a mean 12-month weight change of -8.0 kg, versus -6.3 kg with calorie restriction alone. The net difference of -1.8 kg (95% CI -4.0 to 0.4; P = 0.11) was not statistically significant, and the interval cannot rule out either a real benefit or none.
The New England Journal of Medicine
In a 20-person ward trial, an ultra-processed menu led to more eating and weight gain
In 20 adults living in a hospital research unit for 28 days, an ultra-processed menu led them to eat 508 kcal/day more (± 106 SE, P = 0.0001) and gain 0.9 kg, while a menu of unprocessed foods led to a 0.9 kg loss, each over 2 weeks and with eating left to appetite. The study was small, short and fully provisioned, so it cannot show what happens in daily life or which feature of the foods drove the extra eating.
Cell Metabolism
Mediterranean diet with olive oil or nuts linked to fewer heart events (corrected trial)
Among 7447 Spanish adults aged 55 to 80 at high cardiovascular risk, those assigned to a Mediterranean diet with extra-virgin olive oil (HR 0.69, 95% CI 0.53 to 0.91) or with nuts (HR 0.72, 0.54 to 0.95) had fewer major cardiovascular events than those told to cut dietary fat. The trial had randomisation errors, which is why the 2013 report was withdrawn and the estimates recalculated, so treat this as strong but imperfect evidence.
The New England Journal of Medicine

